How improved sensitivity of bioassays and terminal half-life of drugs impact on bioequivalence trials

Arzneimittel-Forschung/Drug Research

Volumn 59, Issue 1, 2009, Pages 55-58

  Marzo, Antonio ^a   Fontana, Elena ^a  

^a IPAS SA   (Switzerland)

Author keywords

Bioassay; Bioequivalence; Clearance; Guidelines; Terminal half life

Indexed keywords

NORTAMOXIFEN; RAMIPRIL; RAMIPRILAT; TAMOXIFEN;

AREA UNDER THE CURVE; BIOASSAY; BIOEQUIVALENCE; BLOOD SAMPLING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; TANDEM MASS SPECTROMETRY; VOLUNTEER;

EID: 59849115346     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296365     Document Type: Short Survey

References (15)

1. US Dept of Health and Human Services. Guidance for industry. Bioavailability and bioequivalence studies for orally administered drug products: general conditions - Draft guidance; 2002.
2. Note for guidance on the investigation of bioavailability and bioequivalence. CPMP/EWP/QWP/1401/98; 2001.
3. Draft Guideline on the investigation of bioequivalence. Doc. Ref. CPMP/EWP/QWP/1401/98 Rev. 1.
4. Marzo A. Pharmacokinetic analysis, bioavailability and operating guidelines. J Pharm Pharmacol. 1997; 49:1259-60.
5. Marzo A. Open questions in bioequivalence: an updated reappraisal. Curr Clin Pharmacol. 2007; 2:179-89.
6. Marzo A, Ceppi Monti N, Vuksic D. Experimental, extrapolated and truncated areas under the concentration-time curve in bioequivalence trials. Eur J Clin Pharmacol. 1999; 55:627-31.
7. Marzo A. Crossover design in tamoxifen bioequivalence: a borderline situation. J Pharm Pharmacol. 1998; 50:1433-4.
8. Lønning PE, Lien EA, Lundgren S, Kvinnsland S. Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clin Pharmacokinet. 1992; 22:327-58.
9. Marzo A, Dal Bo L. Tandem mass spectrometry (LC-MS-MS): a predominant role in bioassays for pharmacokinetic studies. Arzneimittelforschung. 2007; 57:122-8.
10. Thuillez C, Richer C, Giudicelli JF. Pharmacokinetics, converting enzyme inhibition and peripheral arterial hemodynamics of ramipril in healthy volunteers. Am J Cardiol. 1987; 59:38D-44D.
11. Witte PU, Irmisch R, Hajdú P, Metzger H. Pharmacokinetics and pharmacodynamics of a novel orally active angiotensin converting enzyme inhibitor (HOE 498) in healthy subjects. Eur J Clin Pharmacol. 1984; 27:577-81.
12. Gilchrist WJ, Beard K, Manhem P, Thomas EM, Robertson JI, Ball SG. Pharmacokinetics and effects on the renin-angiotensin system of ramipril in elderly patients. Am J Cardiol. 1987; 59:28D-32D.
13. Lu XY, Shen-Tu JZ, Liu J. High-performance liquid chro-matography-mass spectrometric analysis of ramipril and its active metabolite ramiprilat in human serum: application to a pharmacokinetic study in the Chinese volunteers. J Pharm Biomed Anal. 2006; 40:478-83.
14. Mendes GD, Dantas Sanfelice AT, do Carmo Borges NC, Cavedal LE, Sverdloff C, Prado Galuppo M, et al. Comparative bioavailability of two ramipril formulations after single-dose administration in healthy volunteers. Int J Clin Pharmacol Ther. 2006; 44:93-8.
15. Eckert HG, Badian MJ, Gantz D, Kellner HM, Volz M. Pharmacokinetics and biotransformation of 2-[N-[(S)-l-ethoxy-carbonyl-3-phenylpropyl]-L-alanyl]-(1S, 3S,5S)-2-azabicyclo-[3.3.0]octane-3-carboxylic acid (Hoe 498) in rat, dog and man. Arzneimittelforschung. 1984;34:1435-47.